Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announces the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States. The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.
Read the full article: Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility in Rockville, Maryland //
Source: https://www.prnewswire.com/news-releases/samsung-biologics-completes-acquisition-of-gsks-manufacturing-facility-in-rockville-maryland-302729835.html